American Preclinical Services

CLOSEOUT LETTER American Preclinical Services MARCS-CMS 562382 — August 09, 2021 More Warning Letters Warning Letters About Warning and Close-Out Letters Product: Medical Devices Recipient: Recipient Name Michael Conforti, DVM, MS, MBA Recipient Title Vice President of Preclinical Operations American Preclinical Services 8945 Evergreen Blvd NW Minneapolis , MN 55433-6043 United States Issuing Office: Center for Devices and Radiological Health United States Dear Dr. Conforti: The purpose of this letter is to inform you that the Food and Drug Administration (FDA) inspection conducted at your clinical site from May 10, 2021 to May 21, 2021 revealed no significant concerns. The FDA has completed an evaluation of your firm’s corrective and preventive actions in response to our Warning Letter (WL) dated February 12, 2019. Based on our evaluation, it appears that your firm has adequately addressed the violations contained in this WL and has implemented the corrective actions, as promised in your response letters, dated October 25, 2018, November 9, 2018, November 30, 2018, December 11, 2018, March 1, 2019, April 8, 2019 and June 14, 2019. This letter does not relieve your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 321(h), and its implementing regulations. The FDA expects your firm to maintain compliance and this letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely yours, /S/ Sheena A. Green, MS Assistant Director DCEA1: Division of Clinical Science and Quality OCEA: Office of Clinical Evidence and Analysis Office of Product Evaluation and Quality Center for Devices and Radiological Health Content current as of: 08/13/2021 Regulated Product(s) Medical Devices